Betahistine Dihydrochloride API Manufacturers & Suppliers

Looking for Betahistine Dihydrochloride API 5579-84-0?

Description:

Here you will find a list of producers, manufacturers and distributors of Betahistine Dihydrochloride. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Betahistine Dihydrochloride 

Synonyms:

Betahistine Hydrochloride  

Cas Number:

5579-84-0 

Betahistine Dihydrochloride is a type of Anti-vertigo agents

Anti-vertigo agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are used to treat vertigo, a condition characterized by a sensation of dizziness, spinning, or loss of balance. These APIs are specifically designed to target the underlying causes of vertigo and provide relief to patients suffering from this debilitating condition.

The primary mechanism of action of anti-vertigo agents involves their ability to modulate the central nervous system (CNS) and peripheral vestibular system. By acting on specific receptors and neurotransmitters in the brain and inner ear, these APIs help regulate the balance and coordination signals transmitted by the vestibular system, thus reducing the symptoms of vertigo.

Some commonly used anti-vertigo APIs include meclizine, betahistine, and dimenhydrinate. Meclizine, for instance, is an antihistamine that blocks histamine receptors in the brain and effectively alleviates vertigo symptoms. Betahistine, on the other hand, acts as a histamine H1 receptor agonist and H3 receptor antagonist, improving blood flow in the inner ear and reducing the frequency and severity of vertigo episodes. Dimenhydrinate, a combination of diphenhydramine and 8-chlorotheophylline, exerts its anti-vertigo effects by blocking histamine receptors and exerting a sedative effect on the CNS.

Anti-vertigo agents are available in various formulations, including oral tablets, sublingual tablets, and transdermal patches, providing options for patients with different preferences and needs. These APIs have shown efficacy in managing vertigo and are commonly prescribed by healthcare professionals. However, it is important to note that these medications may have potential side effects, such as drowsiness, dry mouth, or gastrointestinal disturbances, which should be considered when prescribing them to patients.

In conclusion, anti-vertigo agents are a vital category of pharmaceutical APIs that play a crucial role in the management of vertigo. By targeting the underlying causes of this condition, these APIs provide symptomatic relief and improve the quality of life for individuals suffering from vertigo.